NEW YORK Could U.S. healthcare reform improve the industry's profit prognosis?
NEW YORK Fred Hassan, former head of Schering-Plough Corp, said Merck & Co is likely to prevail over Johnson & Johnson in its battle to retain overseas rights to the blockbuster arthritis drug Remicade.
NEW YORK The head of the U.S. Food and Drug Administration defended the agency's decision not to use an additive that could have stretched swine flu vaccine supplies, adding that doses should be coming more regularly. | Video
NEW YORK Drugmakers who have complained for years about caution and unpredictability at the U.S. Food and Drug Administration see signs the climate for reviewing new medicines may be improving.
NEW YORK Sales of flu treatments due to the H1N1 swine flu pandemic may be sustainable beyond the current winter season, as governments around the world overhaul their long-term strategy on stockpiles.
NEW YORK The U.S. Food and Drug Administration is working to increase the speed of drug reviews and clean up problems in the division that oversees medical devices, the agency's commissioner said on Thursday.
NEW YORK GlaxoSmithKline Plc does not expect profit margins to slip substantially, despite an aggressive drive to diversify into areas like emerging markets and consumer health, its chief executive said on Thursday.
NEW YORK The new head of the U.S. Food and Drug Administration said she is working to clean up the agency's troubled device unit, including a review of how it approves medical devices.
NEW YORK GlaxoSmithKline Plc said on Thursday it expects its experimental lupus drug Benlysta to be a "very major" product and contribute meaningfully to the company's bottom line.
NEW YORK Cash-strapped hospitals are stepping up pressure on the prices of medical devices -- from knee replacements to diagnostic tests and surgical systems -- as momentum builds toward U.S. healthcare reform.
NEW YORK Pfizer Inc Chief Executive Officer Jeffrey Kindler said the drugmaker is integrating its Wyeth purchase far faster than previous big acquisitions, and it will no longer be overly dependent on one or two blockbuster medications.